Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Portfolio Pulse from
Merus N.V. has initiated a Phase 2 trial for petosemtamab, a Biclonics® targeting EGFR and LGR5, in heavily pretreated metastatic colorectal cancer patients. The first patient has been dosed, marking a significant step in their clinical development.
December 16, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus N.V. has dosed the first patient in its Phase 2 trial of petosemtamab for metastatic colorectal cancer, indicating progress in their clinical pipeline.
The initiation of a Phase 2 trial and dosing of the first patient is a positive development for Merus N.V., as it demonstrates progress in their clinical pipeline. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90